Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980902 | 1.00 | BACE1 (0.56) | BACE1BACE2CYP2D6 | |
| SCHEMBL13268458 | 0.83 | BACE1 (0.58) | BACE1BACE2CYP2D6 | |
| SCHEMBL13268459 | 0.83 | BACE1 (0.58) | BACE1BACE2CYP2D6 | |
| SCHEMBL1976031 | 0.83 | BACE1 (0.55) | BACE1BACE2CYP2D6 | |
| SCHEMBL1976028 | 0.83 | BACE1 (0.55) | BACE1BACE2CYP2D6 | |
| SCHEMBL2592463 | 0.82 | BACE1 (0.56) | BACE1BACE2 | |
| SCHEMBL2593857 | 0.82 | BACE1 (0.56) | BACE1BACE2 | |
| SCHEMBL2588729 | 0.82 | BACE1 (0.57) | BACE1BACE2 | |
| SCHEMBL2588722 | 0.82 | BACE1 (0.57) | BACE1BACE2 | |
| SCHEMBL17907548 | 0.80 | BACE1 (0.52) | BACE1BACE2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511268-B2 | OXAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2021-02-17 | — | — | EP | claimed |
| EP-2511268-B1 | OXAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2016-07-13 | — | — | EP | claimed |
| EP-2509966-B1 | AMINO OXAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | claimed |
| EP-2509966-A1 | AMINO OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | claimed |
| US-9656974-B2 | Oxazine derivatives | SHIONOGI & CO., LTD. (JP) | 2017-05-23 | — | — | US | disclosed |
| US-9656974-B2 | Oxazine derivatives | SHIONOGI & CO., LTD. (JP) | 2017-05-23 | — | — | US | disclosed |
| US-20160159757-A1 | OXAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159757-A1 | OXAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160090360-A1 | SYNTHESIS OF BACE INHIBITORS | HOFFMANN LA ROCHE (US) | 2016-03-31 | — | — | US | disclosed |
| US-9290466-B2 | Oxazine derivatives | SHIONOGI & CO., LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9290466-B2 | Oxazine derivatives | SHIONOGI & CO., LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20150166491-A1 | OXAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| EP-2509966-A1 | AMINO OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120238557-A1 | AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER | SHIONOGI & CO., LTD. (JP) | 2012-09-20 | — | — | US | disclosed |
| US-20120238557-A1 | AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER | SHIONOGI & CO., LTD. (JP) | 2012-09-20 | — | — | US | disclosed |
| EP-2500344-A1 | AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER | Shionogi&Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-7964594-B1 | Amino oxazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238557-A1 | AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER | APP, APBA1, SLC1A5 | BACE1 12/4885BACE2 112/4885CYP2D6 2122/4885 |
| US-20150166491-A1 | OXAZINE DERIVATIVES | APP, BACE1, PSEN1 | BACE1 2/4885BACE2 8/4885CYP2D6 1039/4885 |
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885CYP2D6 187/4885 |
| US-20160159757-A1 | OXAZINE DERIVATIVES | APP, BACE1, PSEN1 | BACE1 2/4885BACE2 8/4885CYP2D6 1039/4885 |
| US-20160090360-A1 | SYNTHESIS OF BACE INHIBITORS | BACE2, BACE1, APP | BACE1 2/4885BACE2 1/4885CYP2D6 302/4885 |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | BACE1 2/4885BACE2 1/4885CYP2D6 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.